Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors

Cai, Ming; Ni, Wei‐Jian; Wang, Yinghong; Wang, Jing-Ji; Zhou, Hong

doi:10.3389/fonc.2022.906372

Cited by 3 publications

(3 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Involvement of TMEM88 in different malignancies has been reported by different research groups worldwide ( 15 , 16 ). For example, low TMEM88 expression was identified in both thyroid cancer specimens and corresponding cell lines.…”

Section: Discussionmentioning

confidence: 95%

Transmembrane protein 88 suppresses hepatocellular carcinoma progression and serves as a novel prognostic factor

Chen¹,

Song³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundTransmembrane protein 88 (TMEM88) is known to be involved in the canonical Wnt signaling pathway and is implicated in several malignancies. However, the expression, function, and prognostic significance of TMEM88 in hepatocellular carcinoma (HCC) remain unclear.MethodsIn this study, we analyzed mRNA levels of TMEM88 in HCC specimens from the TCGA dataset (n=374) to explore the correlation between TMEM88 and HCC. We also overexpressed TMEM88 in the Huh7 human HCC cell line to investigate its tumor-related role in HCC. Additionally, we conducted in vivo experiments using a mouse model to further validate the critical function of TMEM88 in modulating HCC growth.ResultsOur results showed that TMEM88 is negatively correlated with the T stage, TNM stage, and pathological grade of HCC. Higher levels of TMEM88 can help predict better overall survival of HCC in both univariate and multivariate analyses. Similarly, higher TMEM88 is a novel prognostic factor for better disease-specific survival of HCC. Overexpression of TMEM88 in Huh7 cells led to a decreased cell proliferation capacity. Xenograft experiments in a mouse model showed that TMEM88 overexpression can remarkably suppress HCC progression.ConclusionsTransmembrane protein 88 suppresses HCC growth both in vitro and in vivo, which can act as a potential prognostic factor with clinical application potential.

show abstract

Section: Discussionmentioning

confidence: 95%

Transmembrane protein 88 suppresses hepatocellular carcinoma progression and serves as a novel prognostic factor

Chen¹,

Song³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In humans, TMEM88 is involved in cardiomyocyte differentiation and heart development by downregulating the Wnt/β-catenin pathway ( 79 ). In cancer, TMEM88 has been associated with a tumor suppressor and oncogenic function determined by its cellular location ( 25 , 72 ). It was reported that in NSCLC, they identified the expression of TMEM88 in the plasma membrane and in the cytosol.…”

Section: Tmem Proteins With a Dual Function In Different Types Of Cancermentioning

confidence: 99%

The transmembrane proteins (TMEM) and their role in cell proliferation, migration, invasion, and epithelial-mesenchymal transition in cancer

Herrera-Quiterio,

Encarnación-Guevara

2023

Front. Oncol.

View full text Add to dashboard Cite

Transmembrane proteins (TMEM) are located in the different biological membranes of the cell and have at least one passage through these cellular compartments. TMEM proteins carry out a wide variety of functions necessary to maintain cell homeostasis TMEM165 participates in glycosylation protein, TMEM88 in the development of cardiomyocytes, TMEM45A in epidermal keratinization, and TMEM74 regulating autophagy. However, for many TMEM proteins, their physiological function remains unknown. The role of these proteins is being recently investigated in cancer since transcriptomic and proteomic studies have revealed that exits differential expression of TMEM proteins in different neoplasms concerning cancer-free tissues. Among the cellular processes in which TMEM proteins have been involved in cancer are the promotion or suppression of cell proliferation, epithelial-mesenchymal transition, invasion, migration, intravasation/extravasation, metastasis, modulation of the immune response, and response to antineoplastic drugs. Inclusive data suggests that the participation of TMEM proteins in these cellular events could be carried out through involvement in different cell signaling pathways. However, the exact mechanisms not clear. This review shows a description of the involvement of TMEM proteins that promote or decrease cell proliferation, migration, and invasion in cancer cells, describes those TMEM proteins for which both a tumor suppressor and a tumor promoter role have been identified, depending on the type of cancer in which the protein is expressed. As well as some TMEM proteins involved in chemoresistance. A better characterization of these proteins is required to improve the understanding of the tumors in which their expression and function are altered; in addition to improving the understanding of the role of these proteins in cancer will show those TMEM proteins be potential candidates as biomarkers of response to chemotherapy or prognostic biomarkers or as potential therapeutic targets in cancer.

show abstract

“…The overall prognosis for patients with DTC is favorable, while patients with distant metastases have a significantly poorer prognosis [ 7 , 8 ]. The lung is the most commonly affected site of distant metastases for DTC metastases, with an incidence rate of 2–20% [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

The Effect of Radioiodine Therapy on the Prognosis of Differentiated Thyroid Cancer with Lung Metastases

Zhang,

Zhu,

Zhang

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Lung metastasis substantially influences the survival of thyroid cancer (TC) patients. This study sought to investigate factors impacting the survival of differentiated thyroid cancer patients with lung metastases (DTC–LM) undergoing radioiodine therapy (RAI) after thyroid surgery. The retrospective study encompassed 609 TC patients with lung metastases. Survival outcomes—specifically, overall survival (OS) and thyroid cancer-specific survival (TCSS)—were examined through both univariate and multivariate Cox regression analyses. Radioiodine therapy (RAI)’s impact on DTC–LM patient survival was further assessed with the Kaplan–Meier survival curve. Of the 609 TC patients with lung metastases, 434 (71.3%) were found to have undergone thyroid surgery after a median follow-up of 59 months. Anaplastic thyroid cancer (ATC), stage IV, and lung metastases associated with other metastases were identified as risk factors for OS and TCSS in TCLM patients. RAI therapy significantly enhances survival in DTC–LM patients followed by primary site surgery under the age of 55, PTC patients, and those with single organ metastases at lung.

show abstract

Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors

Cited by 3 publications

References 76 publications

Transmembrane protein 88 suppresses hepatocellular carcinoma progression and serves as a novel prognostic factor

Transmembrane protein 88 suppresses hepatocellular carcinoma progression and serves as a novel prognostic factor

The transmembrane proteins (TMEM) and their role in cell proliferation, migration, invasion, and epithelial-mesenchymal transition in cancer

The Effect of Radioiodine Therapy on the Prognosis of Differentiated Thyroid Cancer with Lung Metastases

Contact Info

Product

Resources

About